Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Taysha Gene Therapies made a bold debut with $30 million in seed financing and a pipeline of 15 preclinical gene therapies for diseases of the central nervous system. The Dallas-based start-up will rely on the University of Texas Southwestern Medical Center’s gene therapy program—led by Steven Gray and Berge Minassian—for drug discovery, preclinical research, and clinical manufacturing of adeno-associated virus-based gene therapies. Sean Nolan, former CEO of AveXis, which makes the gene therapy Zolgensma, leads Taysha’s board of directors.
This article has been sent to the following recipient: